Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronedarone (Primary)
  • Indications Atrial fibrillation; Cardiovascular disorders
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms PALLAS
  • Sponsors Sanofi
  • Most Recent Events

    • 06 Apr 2022 This trial has been completed in Netherland (End Date: 21 Sep 2011), according to European Clinical Trials Database record.
    • 05 Oct 2021 This trial has been completed in Spain (End Date: 21 Sep 2011), according to European Clinical Trials Database record.
    • 20 Sep 2011 New source identified and integrated (Clinical Trials Registry- India).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top